BioSpace News Archive

Agenus subsidiary, SaponiQx, a leader in saponin-based adjuvant discovery and production, announces a pivotal advancement in vaccine research and production with the availability of cGMP (current good manufacturing practice) STIMULON™ cultured plant cell (cpc) QS-21. STIMULON cpcQS-21 is a sustainable and cost-efficient alternative to conventionally extracted QS-21 from bark extract, used in high-performance vaccines such as SHINGRIX and AREXVY.

Helsinn Group announces the signing of a new financing agreement with BancaStato, effective from September 2023.

ImmPACT Bio USA , Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for IMPT-514, a potential first-in-class CD19/CD20 CAR-T therapy for the treatment of patients with active refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE).

Aruna Bio, Inc. today announced that Stephen From, Chief Executive Officer of Aruna Bio, will be presenting a corporate overview at the BIO Investor Forum being held October 17-18, 2023, in San Francisco, CA.

Ovid Therapeutics Inc. today announced that management will participate in a presentation at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 3:30 p.m. ET in New York.

OrthoPediatrics Corp. announced the limited release of the DF2® Brace as part of its expansion in the non-surgical business for treating kids with musculoskeletal injuries.

Stem Pharm, Inc. and Verge Genomics, announced a collaboration to develop a disease model to validate novel targets identified by Verge for Parkinson’s disease (PD).

I-Mab today announced multiple recent developments in TJ-L14B/ABL503, a differentiated PD-L1 x 4-1BB bispecific antibody developed in collaboration with ABL Bio (Kosdaq: 298380).

Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 31, 2023.

Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, highlighted the inclusion of Generalized Arterial Calcification of Infancy (GACI), which is caused by mutations in the ENPP1 or ABCC6 genes, in the Genomic England’s Generation Study.